Literature DB >> 26097061

Foldamers as Anticancer Therapeutics: Targeting Protein-Protein Interactions and the Cell Membrane.

Sara Fahs1,2, Yogita Patil-Sen1, Timothy J Snape1.   

Abstract

Targeting important protein-protein interactions involved in carcinogenesis or targeting the cell membrane of a cancer cell directly are just two of the ways in which foldamers (oligomeric molecules that fold into distinct shapes in solution) hold considerable potential in the treatment of cancer. From mimicking the local topography of the helical compound of interest by using covalently constrained foldamers to mimicking the topography of the natural helix such that the positions of key functional motifs are in an identical spatial orientation to match those presented by the original α-helix, synthetic foldamers have been used to mimic the natural foldamers that interact with proteins or the cell membrane. These targeted approaches have become established over a timeframe of more than a decade, and they continue to be included in the assortment of cancer targets being studied and the arsenal of chemotherapy compounds in development. These approaches are reviewed herein.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  anticancer agents; foldamers; helix mimics; membranes; peptides; protein-protein interactions

Year:  2015        PMID: 26097061     DOI: 10.1002/cbic.201500188

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  2 in total

Review 1.  Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review).

Authors:  Wararat Chiangjong; Somchai Chutipongtanate; Suradej Hongeng
Journal:  Int J Oncol       Date:  2020-07-10       Impact factor: 5.650

2.  Conformationally Programmable Chiral Foldamers with Compact and Extended Domains Controlled by Monomer Structure.

Authors:  Zachariah Lockhart; Peter C Knipe
Journal:  Angew Chem Int Ed Engl       Date:  2018-06-12       Impact factor: 15.336

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.